Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited Fundamental Analysis
Sino Biopharmaceutical Limited (1177.HK) shows weak financial fundamentals with a PE ratio of 32.82, profit margin of 7.36%, and ROE of 7.24%. The company generates $31.6B in annual revenue with strong year-over-year growth of 10.18%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 44.8/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1177.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1177.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate1177.HK shows balanced valuation metrics.
Growth Score
Excellent1177.HK delivers strong and consistent growth momentum.
Financial Health Score
Excellent1177.HK maintains a strong and stable balance sheet.
Profitability Score
Weak1177.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1177.HK Expensive or Cheap?
P/E Ratio
1177.HK trades at 32.82 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 1177.HK's PEG of 1.27 indicates fair valuation.
Price to Book
The market values Sino Biopharmaceutical Limited at 2.51 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.33 times EBITDA. This is generally considered low.
How Well Does 1177.HK Make Money?
Net Profit Margin
For every $100 in sales, Sino Biopharmaceutical Limited keeps $7.36 as profit after all expenses.
Operating Margin
Core operations generate 21.84 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.24 in profit for every $100 of shareholder equity.
ROA
Sino Biopharmaceutical Limited generates $3.08 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sino Biopharmaceutical Limited generates limited operating cash flow of $3.14B, signaling weaker underlying cash strength.
Free Cash Flow
Sino Biopharmaceutical Limited produces free cash flow of $2.87B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.16 in free cash annually.
FCF Yield
1177.HK converts 3.79% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
32.82
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.27
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.51
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.40
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.52
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.37
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How 1177.HK Stacks Against Its Sector Peers
| Metric | 1177.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 32.82 | 28.32 | Worse (Expensive) |
| ROE | 7.24% | 733.00% | Weak |
| Net Margin | 7.36% | -53055.00% (disorted) | Weak |
| Debt/Equity | 0.52 | 0.38 | Weak (High Leverage) |
| Current Ratio | 1.37 | 4.03 | Neutral |
| ROA | 3.08% | -19488.00% (disorted) | Weak |
1177.HK outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sino Biopharmaceutical Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-32.85%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-57.97%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-100.00%
Industry Style: Defensive, Growth, Innovation
Declining